Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Sagar Lonial is Professor, Chair and Chief Medical Officer in the Department of Hematology and Medical Oncology at Winship Cancer Institute at Emory University School of Medicine in Atlanta, Georgia. Dr. Lonial completed his medical degree at the University of Louisville School of Medicine in Kentucky. He completed his internship and residency at Baylor College of Medicine in Houston, Texas; served as Chief Medical Resident at the Ben Taub General Hospital and the Texas Heart Institute at St. Luke’s Hospital; and completed a fellowship in hematology/oncology at Emory University School of Medicine.
Board certified in hematology and medical oncology, Dr. Lonial is internationally recognized as a leading authority in multiple myeloma treatment and research. He is involved in numerous professional organizations, including the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Blood and Marrow Transplantation. He is Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the board of directors for the International Myeloma Society and the scientific Advisory Board for the International Myeloma Foundation. He is also a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University.
Dr. Lonial’s recent research has focused on combinations of novel agents as therapy for myeloma and lymphoma, and particularly on evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation, and The Leukemia & Lymphoma Society (LLS). Dr. Lonial has authored over 200 peer-reviewed publications. He serves on the editorial board of the Journal of Clinical Oncology and Leukemia; is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia; and is the hematologic malignancies section editor for the journal Cancer. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine and others.